Navigation Links
Abbott Announces EuroPCR 2009 Activities
Date:5/18/2009

- New data to be presented on Abbott's market-leading XIENCE V(R) stent

- Educational information available on XIENCE PRIME(TM), Abbott's next-generation drug eluting stent in development

BARCELONA, Spain, May 18 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced the company's schedule of major events and news announcements during EuroPCR 2009 in Barcelona, May 19 - 22. These include the presentation of new data from the SPIRIT V post-approval, single-arm study of the company's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System, as well as new details of Abbott's next-generation drug eluting stent in development, the XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System.

During the meeting at Abbott's booth (# CO8), physicians will learn more about XIENCE PRIME, which utilizes the same drug and polymer as Abbott's market-leading XIENCE V drug eluting stent and is based upon the proven design of the MULTI-LINK(R) family of stents. Building upon the strong body of clinical evidence from the SPIRIT family of clinical trials, Abbott plans to make XIENCE PRIME available in an expanded size matrix, including XIENCE PRIME SV for small vessels and XIENCE PRIME LL for long lesions. The company expects to launch XIENCE PRIME in Europe later this year.

XIENCE PRIME is pending CE Mark, and is not available for sale.

In addition, Eberhard Grube, M.D., of Heart Center Siegburg, Germany, will present the one-year results from Abbott's 2,663-patient SPIRIT V single-arm study. The data will be presented during the EuroPCR 2009 Drug-Eluting Stent Abstract Session on Thursday, May 21, at 3:06 p.m. CET in Room 118-119 at The Forum CCIB Convention Center in Barcelona.

"We are excited to present the one-year data from the SPIRIT V study. This single-arm trial accurately reflects the broad range of disease seen in a typical catheterization lab and will provide valuable information on how XIENCE V performs in complex lesions in a real-world population," said Charles Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. "In addition, we will be demonstrating the use of XIENCE PRIME, the next innovation from our pipeline, through simulated arterial model (SAM) testing at EuroPCR."

More Featured Products and Programs at Abbott's Booth

  • Prostar XL: Physicians can learn about the Prostar XL Percutaneous Vascular Surgical System vessel closure device, which now has CE Mark for use following minimally invasive procedures that allow large access sites up to 24F in the femoral artery in the upper thigh. The Prostar XL currently is the only vessel closure device with this indication in the European Union.
  • Emboshield Nav6: Abbott will feature its sixth-generation Emboshield(R) NAV6 Embolic Protection System, which is used during carotid stenting procedures to prevent particles of dislodged plaque from flowing to the brain, potentially causing an ischemic stroke. The advanced design of the Emboshield NAV6 offers simpler procedure preparation and excellent deliverability and visibility under X-ray, providing ease of use even in challenging anatomies.
  • Bioabsorbable Program: Richard Rapoza, Ph.D., divisional vice president, Bioabsorbable Vascular Solutions Program, Abbott Vascular, will present "The Future of Coronary Stenting: Bioabsorbable Stent Technology" on May 20 and 21 from 12:15 - 12:45 p.m. CET. Dr. Rapoza will discuss Abbott's ABSORB clinical trial, which recently began enrolling patients into the second phase of the trial. Abbott is the only company with long-term clinical data (out to two years) evaluating the safety and performance of a fully bioabsorbable coronary device.

About XIENCE V

Abbott's market-leading XIENCE V drug eluting stent is marketed in the United States, Europe and other international markets. XIENCE V is an investigational device in Japan and is currently under review by Japan's Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency.

Additional information about XIENCE V, including important safety and effectiveness information, is available online at www.xiencev.com.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


'/>"/>
SOURCE Abbott Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Victory! Colombian Government Cuts Price of Abbotts Lifesaving AIDS Drug Kaletra 55%, Says AHF
2. Dr. Abbott J. Krieger Joins Avery Biomedical Devices, Inc. as Chief Clinical Liaison
3. Abbott Highlights Strong Corporate Responsibility Performance With Release of 2008 Global Citizenship Report
4. Abbott Annual Meeting Highlights Outstanding 2008 Results, Continued Strong Outlook
5. Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009
6. Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease
7. Abbott Hosts Conference Call for First-Quarter Earnings
8. Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter
9. Abbott to Present at Cowen Annual Health Care Conference
10. Abbott Announces Required Offer to Repurchase Convertible Senior Subordinated Notes of Its AMO Subsidiary
11. Abbott Completes Acquisition of Advanced Medical Optics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... ... March 01, 2017 , ... Physicians’ ... on April 8, 2017, in Sunny Isles Beach, Florida. The conference will be ... Physicians Organization, Boston, and Dr. Heather Wakelee, associate professor of medicine (oncology), Stanford ...
(Date:3/1/2017)... Texas (PRWEB) , ... March 01, 2017 , ... Hennessey Performance (HPE) today announced its ... bumped the Ford EcoBoost 3.5L twin turbo V6 engine from 450 bhp and 510 lb-ft ... twist yield a 0-60 mph time of just 4.2 seconds while running down the ¼ ...
(Date:3/1/2017)... ... 01, 2017 , ... Financial Recovery Group, Inc. (FRG), is proud to announce ... Nashville, Tenn. The company also is offering a special discount for those who attend ... year, brings together the brightest minds in the healthcare industry to share information on ...
(Date:3/1/2017)... ... , ... Look for a new collection of edible berry plants from the ... and Plants is launching their new Bushel and Berry Collection , formerly BrazelBerries, ... growing fresh fruit simple with a variety of easy-to-grow, low-maintenance container berry plants. These ...
(Date:3/1/2017)... ... ... On January 27, 2017, Laffey, Bucci & Kent together with a local ... Circuit Court of Kanawha County, West Virginia. The lawsuit was filed on behalf of ... and T.B. v. Seventh-Day Adventist Church et al. Case #: 17-C-146. , ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... PRUSSIA, Pa. , March 1, 2017  Global ... it has completed the largest ever Chronic Inflammatory Demyelinating ... A nd T reatment with H ... designed to demonstrate the efficacy, safety and tolerability of ... Hizentra ® (Immune Globulin Subcutaneous [Human]), compared with ...
(Date:3/1/2017)... Pharmaceutical Care Management Association (PCMA) issued the following statement ... nomination of Seema Verma as the new ... "The popular Medicare Part D program continues to ... offering an abundance of competing plan choices in each ... and home delivery, the program is a win-win for ...
(Date:3/1/2017)... global  Intraoperative Neuromonitoring (IONM) market  is expected to reach USD 3.6 billion by ... neuromonitoring market is anticipated to witness significant growth in the forecast period, which ... of surgeries. Continue Reading ... ... ...
Breaking Medicine Technology: